Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.79
(
-1.85%
)
Bitcoin
74,031.35
(
0.12%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 151688

Saturday, 11/03/2012 12:54:28 PM

Saturday, November 03, 2012 12:54:28 PM

Post# of 257253

Seems that Gilenya share comes a lot more at the expense of the beta interferon class than of Copaxone and Tysabri.

This has been the case, albeit to a lesser degree, ever since the Gilenya launch—see, for instance, the chart in #msg-65574194.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now